Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News

September 24, 2007 - Stentys announced that its drug-eluting bifurcated stent for treatment of blocked coronary artery ...

Home September 23, 2007
Home
News

September 21, 2007-The CYPHER Sirolimus-eluting Coronary Stent reduced by more than half the rate of major adverse ...

Home September 20, 2007
Home
News

September 18, 2007 - Angiotech Pharmaceuticals Inc. announced that it reached a favorable agreement with Johnson & ...

Home September 17, 2007
Home
News

September 14, 2007 - In the largest study of its kind to date, comparing the CYPHER Sirolimus-eluting Coronary Stent and ...

Home September 13, 2007
Home
News

September 10, 2007 - Four analyses of three-year follow-up data that were presented at the ESC Congress 2007 showed that ...

Home September 09, 2007
Home
Feature | Cristen C. Bolan

Just when drug-eluting stents (DES) were going to revolutionize interventional cardiology, new reports that DES ...

Home September 09, 2007
Home
Feature

iffering approaches for the treatment of coronary bifurcation and ostial lesions (CBOL) continue to feed the ...

Home September 09, 2007
Home
News

September 5, 2007 – According to Boston Scientific Corp., results from the TAXUS WOMAN study, a gender specific analysis ...

Home September 05, 2007
Home
News

September 6, 2007 – Boston Scientific Corp. announced at the ESC 2007 conference in Vienna, Austria, that results from ...

Home September 05, 2007
Home
News

September 5, 2007 - Clinical investigators at the European Society of Cardiology Congress 2007 (ESC Congress 2007) ...

Home September 04, 2007
Home
News

August 22, 2007 - Medtronic, Inc. announced it has been informed by the FDA that an Advisory Panel will review the ...

Home August 21, 2007
Home
News

August 13, 2007 – A study published in the Journal of the American College of Cardiology showed that when ...

Home August 12, 2007
Home
News

August 8, 2007 - A U.S. District Court judge enforced a settlement this week between Abbott Laboratories Inc. and ...

Home August 07, 2007
Home
News

July 19, 2007 – Abbott announced that the first patient was enrolled in its XIENCE V SPIRIT WOMEN clinical trial, the ...

Home July 19, 2007
Home
News

Source: Wall Street Journal Online


July 20, 2007 - U.S. doctors implanted fewer coronary stents in June than any other ...

Home July 19, 2007
Home
Subscribe Now